Open AccessOutcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia
Author(s) -
Soon Hin How,
Chong Kin Liam,
Muhammad Adil Zainal Abidin,
Harissa Husainy Hasbullah,
Lye Mun Tho,
Gwo Fuang Ho,
Ibtisam Muhamad Nor,
Yong Kek Pang,
Kean F Ho,
Muthukkumaran Thiagarajan,
Roziana Ariffin,
Azlina Samsudin,
Azza Omar,
Sin Nee Tan,
Choo Khoon Ong,
Sing Yang Soon,
Mau Ern Poh
Publication year - 2022
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s364713
Subject(s) - southeast asia , mutant , developing country , oncology , medicine , business , environmental health , biology , genetics , gene , ecology , ancient history , history
Although first- and second-generation EGFR TKIs are considered first-line treatment in EGFRm+ NSCLC, most patients develop resistance and progress, commonly, EGFR T790M mutation. The third-generation EGFR-TKI has demonstrated efficacy in patients with progressive disease harboring the T790M mutation and in the first-line setting, bypassing this mode of resistance. The primary objectives of this study are to describe the proportion of EGFR m+ NSCLC patients treated with first-, second- and third-generation EGFR TKIs, and cytotoxic chemotherapy in the first-line setting, and the time on treatment for each category. Secondary objectives are to determine the dropout rate, the rates for T790M mutation testing at disease progression and the type of subsequent treatment.